| Authors: |
Kramlinger VM; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Dalvie D; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Heck CJS; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Kalgutkar AS; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., O'Neill J; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Su D; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Teitelbaum AM; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.)., Totah RA; Translational Medicine, Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts (V.M.K.).; Bristol Myers Squibb, San Diego, California (D.D.).; Medicine Design, Pfizer Worldwide Research, Groton, Connecticut (C.J.S.H.); Medicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts (A.S.K.); Charles River Laboratories Edinburgh Ltd, Tranent, Scotland (J.O.); Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (D.S.).; Drug Metabolism and Pharmacokinetics Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut (A.M.T.); and Medicinal Chemistry, University of Washington, Seattle, Washington (R.A.T.). |
